Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexaria Corp. (Lexaria Bioscience Corp.) on April 7, 2010, covering events occurring on April 1, 2010. The company is incorporated in Nevada and is based in Vancouver, British Columbia, Canada.
Key Financial Metrics and Transaction Details
The filing discloses the creation of a direct financial obligation through a private placement of debt:
- Principal Amount: US $75,000
- Instrument: Non-secured, 18% interest-bearing Promissory Note
- Purchaser: CAB Financial Services Ltd., a company controlled by Chris Bunka (President, CEO, and Director)
- Maturity Date: April 1, 2012 (subject to mutual agreement for April 1, 2011)
- Prepayment Terms: 108% of outstanding principal plus accrued interest
- Conversion Price: $0.30 per common share (voluntary by purchaser)
- Forced Conversion Triggers:
- 50% conversion if stock trades at or above $0.55 for 20 consecutive trading days.
- 100% conversion if stock trades at or above $1.00 for 20 consecutive trading days.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels outside of this specific transaction.
Material Changes and Related Party Transaction
The primary material change is the entry into a definitive agreement with a related party. The issuance of the Promissory Note was made to a non-US person pursuant to the exemption from registration provided by Regulation S under the Securities Act of 1933.
Outlook, Risks, and Contingencies
The filing does not contain management commentary on future outlook, general risks, or contingencies beyond the terms of the Promissory Note. The transaction introduces a dilution risk to existing shareholders if the stock price meets the specified thresholds for forced conversion.
Key Facts for Investor Verification
- Verify the related-party nature of the transaction with Chris Bunka and CAB Financial Services Ltd.
- Confirm the current outstanding principal and accrued interest on the $75,000 note.
- Monitor the company's stock price relative to the $0.55 and $1.00 conversion triggers.
- Review the full Purchase Agreement (Exhibit 20.1) and Promissory Note (Exhibit 20.2) for additional covenants or conditions not summarized here.